<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02547649</url>
  </required_header>
  <id_info>
    <org_study_id>V114-006</org_study_id>
    <nct_id>NCT02547649</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)</brief_title>
  <official_title>A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Pneumococcal Vaccine-Naïve Adults 50 Years of Age or Older</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to assess the effect of two different formulations of pneumococcal
      polysaccharide vaccine on safety and immunogenicity of V114 in healthy adults 50 years of age
      and older.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with an Adverse Event</measure>
    <time_frame>Up to Day 44 after vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with a Solicited Injection-site Adverse Event</measure>
    <time_frame>Up to Day 5 after vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with a Solicited Systemic Adverse Event</measure>
    <time_frame>Up to Day 14 after vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) of Serotype-specific Opsonophagocytic Killing Activity</measure>
    <time_frame>Day 30 (one month after vaccination)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentrations (GMCs) of Serotype-specific Immunoglobulin G</measure>
    <time_frame>Day 30 (one month after vaccination)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with a 4-fold Rise from Baseline in GMT of Serotype-specific Opsonophagocytic Killing Activity</measure>
    <time_frame>Baseline and Day 30 (one month after vaccination)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with a 4-fold Rise from Baseline in GMC of Serotype-specific Immunoglobulin G</measure>
    <time_frame>Baseline and Day 30 (one month after vaccination)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">690</enrollment>
  <condition>Pneumococcal Infections</condition>
  <arm_group>
    <arm_group_label>V114 Formulation A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive a single 0.5 mL intramuscular injection of V114 Formulation A on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>V114 Formulation B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive a single 0.5 mL intramuscular injection of V114 Formulation B on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prevnar 13™</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive a single 0.5 mL intramuscular injection of Prevnar 13™ on Day 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V114 Formulation A</intervention_name>
    <description>Formulation A of V114 containing pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), and 6B (4 mcg) in each 0.5 mL dose</description>
    <arm_group_label>V114 Formulation A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V114 Formulation B</intervention_name>
    <description>Formulation B of V114 containing pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), and 6B (4 mcg) in each 0.5 mL dose</description>
    <arm_group_label>V114 Formulation B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Prevnar 13™</intervention_name>
    <description>Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg each), and 6B (4.4 mcg) in each 0.5 mL dose.</description>
    <arm_group_label>Prevnar 13™</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Good health; any underlying chronic illness must be documented to be in stable
             condition

          -  Highly unlikely to conceive through 6 weeks after administration of the study vaccine

        Exclusion Criteria:

          -  Prior administration of any pneumococcal vaccine

          -  History of invasive pneumococcal disease or known history of other culture-positive
             pneumococcal disease

          -  Known hypersensitivity to any vaccine component

          -  Known or suspected impairment of immune function

          -  Received systemic corticosteroids for &gt;=14 consecutive days and has not completed
             treatment &lt;=30 days prior to study entry, or received systemic corticosteroids
             exceeding physiologic replacement doses within 14 days prior to study vaccination

          -  Coagulation disorder contraindicating intramuscular vaccination

          -  Receives immunosuppressive therapy, including chemotherapeutic agents used to treat
             cancer or other conditions, and treatments associated with organ or bone marrow
             transplantation, or autoimmune disease

          -  Received a blood transfusion or blood products, including immunoglobulins within the 6
             months before receipt of study vaccine or is scheduled to receive a blood transfusion
             or blood product within 30 days of receipt of study vaccine. Autologous blood
             transfusions are not considered an exclusion criterion.

          -  Participated in another clinical study of an investigational product within 2 months
             before the beginning of or any time during the duration of the current clinical study

          -  Breast feeding

          -  User of recreational or illicit drugs or has had a recent history (within the last
             year) of drug or alcohol abuse or dependence
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2015</study_first_submitted>
  <study_first_submitted_qc>September 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2015</study_first_posted>
  <last_update_submitted>February 3, 2016</last_update_submitted>
  <last_update_submitted_qc>February 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

